Charles M. Baum's most recent trade in Acrivon Therapeutics Inc was a trade of 20,275 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 20,275 | 20,275 | - | - | Stock Option (Right to Buy) | |
| PMV Pharmaceuticals Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 33,500 | 33,500 | - | - | Stock Option (right to buy) | |
| Poseida Therapeutics Inc | Charles M. Baum | Director | 08 Jan 2025 | 78,600 | 0 | - | - | Common Stock | ||
| Poseida Therapeutics Inc | Charles M. Baum | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 57,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Charles M. Baum | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Charles M. Baum | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,275 | 20,275 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 27,350 | 27,350 | - | - | Stock Option (Right to buy) | |
| Poseida Therapeutics Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 19,650 | 78,600 | - | 0 | Common Stock | |
| PMV Pharmaceuticals Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 67,500 | 67,500 | - | - | Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 37.00 per share. | 09 Aug 2023 | 54,054 | 227,275 (0%) | 0% | 37 | 1,999,998 | Common Stock |
| Acrivon Therapeutics Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 27,350 | 27,350 | - | - | Stock Option (Right to buy) | |
| Poseida Therapeutics Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 19,650 | 58,950 | - | 0 | Common Stock | |
| PMV Pharmaceuticals Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 21,500 | 21,500 | - | - | Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 7,520 | 7,520 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 4,444 | 173,221 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Sale of securities on an exchange or to another person at price $ 46.60 per share. | 04 Jan 2023 | 3,648 | 168,777 (0%) | 0% | 46.6 | 169,997 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 53,618 | 181,517 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Sale of securities on an exchange or to another person at price $ 40.42 per share. | 19 Dec 2022 | 9,092 | 172,425 (0%) | 0% | 40.4 | 367,469 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2022 | 69,256 | 69,258 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 28 Nov 2022 | 69,256 | 127,899 (0%) | 0% | 100 | 6,925,600 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.41 per share. | 28 Nov 2022 | 69,256 | 197,155 (0%) | 0% | 17.4 | 1,205,747 | Common Stock |
| Poseida Therapeutics Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 57,000 | 57,000 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Charles M. Baum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 39,300 | 39,300 | - | 0 | Common Stock | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 42,325 | 42,325 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 25,543 | 126,713 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 3,703 | 178,052 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.00 per share. | 14 Jan 2022 | 3,703 | 130,416 (0%) | 0% | 27 | 99,981 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Sale of securities on an exchange or to another person at price $ 120.48 per share. | 14 Jan 2022 | 2,517 | 127,899 (0%) | 0% | 120.5 | 303,253 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Sale of securities on an exchange or to another person at price $ 147.73 per share. | 04 Jan 2022 | 4,045 | 101,239 (0%) | 0% | 147.7 | 597,568 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President,Founder,Head of R&D | Sale of securities on an exchange or to another person at price $ 149.09 per share. | 04 Jan 2022 | 69 | 101,170 (0%) | 0% | 149.1 | 10,287 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 2,292 | 100,273 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 26 Jan 2021 | 2,292 | 112,714 (0%) | 0% | 5.4 | 12,377 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 30,742 | 30,742 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 19,665 | 107,177 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 3,245 | 181,755 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.00 per share. | 15 Jan 2021 | 3,245 | 110,422 (0%) | 0% | 27 | 87,615 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 210.28 per share. | 06 Jan 2021 | 4,421 | 87,512 (0%) | 0% | 210.3 | 929,648 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 215.76 per share. | 06 Jan 2021 | 90 | 91,933 (0%) | 0% | 215.8 | 19,418 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Dec 2020 | 10,000 | 92,023 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.49 per share. | 18 Dec 2020 | 40,000 | 142,023 (0%) | 0% | 8.5 | 339,600 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 40,000 | 87,204 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 234.26 per share. | 18 Dec 2020 | 22,932 | 109,203 (0%) | 0% | 234.3 | 5,371,998 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 233.43 per share. | 18 Dec 2020 | 9,888 | 132,135 (0%) | 0% | 233.4 | 2,308,145 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 236.17 per share. | 18 Dec 2020 | 4,250 | 104,460 (0%) | 0% | 236.2 | 1,003,732 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 237.25 per share. | 18 Dec 2020 | 2,020 | 102,440 (0%) | 0% | 237.3 | 479,255 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 235.20 per share. | 18 Dec 2020 | 493 | 108,710 (0%) | 0% | 235.2 | 115,956 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 240.23 per share. | 18 Dec 2020 | 317 | 102,023 (0%) | 0% | 240.2 | 76,153 | Common Stock |
| Mirati Therapeutics Inc | Charles M. Baum | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 238.76 per share. | 18 Dec 2020 | 100 | 102,340 (0%) | 0% | 238.8 | 23,876 | Common Stock |